Most breast lumps are caused by fibrocystic breast changes, also known as fibrocystic breast disease, benign breast disease, mammary dysplasia, or chronic mastitis. In spite of all the scary names, this condition is harmless. At least half of all women have it at some point, usually during their childbearing years.Some of the lumps are solid and some are fluid-filled cysts. (A cyst may form when one of your milk ducts becomes blocked.) No one knows what causes these changes in the breasts, but oestrogen and progesterone, the hormones that control the menstrual cycle, can make lumps or cysts more prominent or painful during the week before your period begins.
Presenting Best breast cancer detection Guide
Early Breast Cancer DetectionBy CHASE of Cashvally.com
Most women are familiar with mammography as our "gold standard" for cancer
screening. However, there are additional tools available that women can add to their arsenal.
One of the most effective tools in cancer screening is self-exam (BSE). However,
BSE works best when women are appropriately trained in the procedure, and then followed-up with
annual clinical exams (CBE) from their physicians.
In a 2000 University of Toronto study, approximately 20,000 women were screened for cancer with BSE and annual CBE, and 20,000 were screened with BSE and mammograms. After more than 10 years, the BSE and annual CBE reported 610 cases of invasive cancer, and 105 deaths. In the BSE and mammogram group, there were 622 cases of invasive cancer and 107 deaths. Without question, the first line of defense against cancer begins with diligent BSE.
Other tools that are available to women include the AMAS (anti-malignan antibody screen) test
and the NMP Nuclear matrix protein) test. Both these are blood tests that measure a certain
protein in the blood that may indicate cancer. The AMAS test has been around for several years
while the NMP test has not been available until only recently. Clinical trials continue in this
area.
One additional tool that may detect an issue early is digital infrared thermal imaging or DITI.
In 1982, the FDA approved thermography as an adjunctive tool for cancer screening. DITI
measures heat emitted from the body and is accurate to 1/100th of a degree. DITI examines
physiology, NOT structure.
It is in this capacity that DITI can monitor HEALTH over time
and alert a patient or physician to a developing problem; possibly before a lump can be seen on
X-ray or palpated clinically. There are no test limitations such as density. DITI is a
non-invasive test that does not emit radiation.
The unique characteristics of cancer allow DITI to detect cancer at an earlier stage of
growth. As cancer is developing, it builds its own blood supply which is then reflected as
increased heat in that particular region of the breast.
DITI has a specificity of 83%; which
reflects a problem in its early stages of development not late-stage cancer as in mammography.
An abnormal thermogram carries a 10-times greater risk for cancer and a persistently abnormal
thermogram carries a 22-times greater risk for cancer.
Clinical research studies continue to support thermography’s role as an adjunctive tool in
breast cancer screening and the ONLY tool that measures health over time. There are now
more than 800 publications on over 300,000 women in clinical trials.
A recent finding published
in the American Journal of Radiology in 2003 showed that thermography has 99% sensitivity in
identifying cancer with single examinations and limited views. Scientists concluded that
a negative thermogram is powerful evidence that cancer is not present.
Breast Cancer Detection Recommended by CHASE, Click Here Now
Here are some more breast growth, breast cancer detection, breast cancer treatment, healthy breast, large breast articles...
